These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20501743)

  • 1. A chemical corrector modifies the channel function of F508del-CFTR.
    Kim Chiaw P; Wellhauser L; Huan LJ; Ramjeesingh M; Bear CE
    Mol Pharmacol; 2010 Sep; 78(3):411-8. PubMed ID: 20501743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability.
    Wellhauser L; Kim Chiaw P; Pasyk S; Li C; Ramjeesingh M; Bear CE
    Mol Pharmacol; 2009 Jun; 75(6):1430-8. PubMed ID: 19339490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine.
    Robert R; Carlile GW; Liao J; Balghi H; Lesimple P; Liu N; Kus B; Rotin D; Wilke M; de Jonge HR; Scholte BJ; Thomas DY; Hanrahan JW
    Mol Pharmacol; 2010 Jun; 77(6):922-30. PubMed ID: 20200141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect.
    Robert R; Carlile GW; Pavel C; Liu N; Anjos SM; Liao J; Luo Y; Zhang D; Thomas DY; Hanrahan JW
    Mol Pharmacol; 2008 Feb; 73(2):478-89. PubMed ID: 17975008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of Phe508 in the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator increases its affinity for the heat shock cognate 70 chaperone.
    Scott-Ward TS; Amaral MD
    FEBS J; 2009 Dec; 276(23):7097-109. PubMed ID: 19878303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
    Yu W; Kim Chiaw P; Bear CE
    J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622.
    Norez C; Bilan F; Kitzis A; Mettey Y; Becq F
    J Pharmacol Exp Ther; 2008 Apr; 325(1):89-99. PubMed ID: 18230692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
    Pasyk S; Li C; Ramjeesingh M; Bear CE
    Biochem J; 2009 Feb; 418(1):185-90. PubMed ID: 18945216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.
    Pasyk S; Molinski S; Ahmadi S; Ramjeesingh M; Huan LJ; Chin S; Du K; Yeger H; Taylor P; Moran MF; Bear CE
    Proteomics; 2015 Jan; 15(2-3):447-61. PubMed ID: 25330774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
    Loo TW; Bartlett MC; Clarke DM
    Mol Pharm; 2005; 2(5):407-13. PubMed ID: 16196493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR.
    Sampson HM; Robert R; Liao J; Matthes E; Carlile GW; Hanrahan JW; Thomas DY
    Chem Biol; 2011 Feb; 18(2):231-42. PubMed ID: 21338920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintaining low Ca2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells.
    Norez C; Antigny F; Becq F; Vandebrouck C
    Traffic; 2006 May; 7(5):562-73. PubMed ID: 16643279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
    Roxo-Rosa M; Xu Z; Schmidt A; Neto M; Cai Z; Soares CM; Sheppard DN; Amaral MD
    Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17891-6. PubMed ID: 17098864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface.
    Eckford PD; Ramjeesingh M; Molinski S; Pasyk S; Dekkers JF; Li C; Ahmadi S; Ip W; Chung TE; Du K; Yeger H; Beekman J; Gonska T; Bear CE
    Chem Biol; 2014 May; 21(5):666-78. PubMed ID: 24726831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth.
    Li H; Yang W; Mendes F; Amaral MD; Sheppard DN
    Am J Physiol Renal Physiol; 2012 Oct; 303(8):F1176-86. PubMed ID: 22874761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.
    Sondo E; Tomati V; Caci E; Esposito AI; Pfeffer U; Pedemonte N; Galietta LJ
    Am J Physiol Cell Physiol; 2011 Oct; 301(4):C872-85. PubMed ID: 21753184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
    Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
    Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.
    Wang Y; Bartlett MC; Loo TW; Clarke DM
    Mol Pharmacol; 2006 Jul; 70(1):297-302. PubMed ID: 16624886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.